Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
65 hedge funds and large institutions have $244M invested in Trillium Therapeutics Inc. in 2020 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
2,673% more capital invested
Capital invested by funds: $8.81M → $244M (+$235M)
1,600% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 3
242% more funds holding
Funds holding: 19 → 65 (+46)
149% more call options, than puts
Call options by funds: $2.08M | Put options by funds: $836K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$18.7M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$15.4M |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$13.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$8.82M |
| 2 |
Morgan Stanley
New York
|
-$6.35M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$1.13M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$323K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$49.1K |
TRIL Hedge Fund Activity: Q1 2020 in Review
65 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2020, worth a combined $244M — up 2,673% from $8.81M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new TRIL positions and 3 closed out — a net gain of 48 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $24M. The largest seller was Sio Capital Management, cutting an estimated $8.82M.
- 65 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2020, up from 19 in Q4 2019.
- Funds reported $244M of Trillium Therapeutics Inc. stock for Q1 2020, up 2,673% quarter-over-quarter.
- 51 funds opened new Trillium Therapeutics Inc. positions in Q1 2020 and 3 closed out, a net change of +48 holders.
- The largest Trillium Therapeutics Inc. buyer in Q1 2020 was RA Capital Management, an estimated $24M added.
- The largest Trillium Therapeutics Inc. seller in Q1 2020 was Sio Capital Management, an estimated $8.82M sold.
Based on aggregated 13F filings for Q1 2020.